Merck Fosamax
Executive Summary
Once-weekly formulation of alendronate approved Oct. 20 for the prevention and treatment of postmenopausal osteoporosis. The product will be available in 35 mg and 70 mg tablets (seven times the existing 5 mg and 10 mg once-daily doses). Merck's distribution of a 40 mg Fosamax formulation for Paget's disease exclusively through CVS ProCare will give the company some pricing flexibility with the new 35 mg formulation (1"The Pink Sheet" Sept. 4, p. 8). The sNDA was filed in December